Several variants of EASIX had been created to predict CRS and ICANS in CAR T-cell therapy, including simplified EASIX (s-EASIX, LDH/ PLT), modified EASIX (m-EASIX, LDH × CRP /PLT), or combined with ferritin and/or CRS for risk stratification [23–25]. The gene discussed is CRP; the disease is congenital rubella syndrome.